Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110


Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD.

Flood VH, Johnsen JM, Kochelek C, Slobodianuk TL, Christopherson PA, Haberichter SL, Udani R, Bellissimo DB, Friedman KD, Montgomery RR.

Res Pract Thromb Haemost. 2018 Jan 23;2(2):390-398. doi: 10.1002/rth2.12077. eCollection 2018 Apr.


Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.


Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.


von Willebrand Disease.

Goodeve A, James P.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2009 Jun 4 [updated 2017 Oct 5].


Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.


Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.

Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Semin Thromb Hemost. 2005 Nov;31(5):577-601. Review.


Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.

Lippi G, Franchini M, Salvagno GL, Montagnana M, Poli G, Guidi GC.

J Thromb Thrombolysis. 2008 Oct;26(2):150-3. Epub 2007 Sep 3.


A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.

Vangenechten I, Mayger K, Smejkal P, Zapletal O, Michiels JJ, Moore GW, Gadisseur A.

J Thromb Haemost. 2018 Jul;16(7):1268-1277. doi: 10.1111/jth.14145. Epub 2018 Jun 6.


Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?

Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.

Thromb Res. 2009 Apr;123(6):862-8. doi: 10.1016/j.thromres.2008.10.008. Epub 2008 Dec 7.


An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.

Akin M, Karapinar DY, Balkan C, Ay Y, Kavakli K.

Clin Appl Thromb Hemost. 2011 Oct;17(5):441-8. doi: 10.1177/1076029610366440. Epub 2010 May 11.


The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.

Delbrück C, Miesbach W.

Acta Haematol. 2019;142(2):71-78. doi: 10.1159/000496820. Epub 2019 May 14.


Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.

Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.

J Thromb Haemost. 2017 Aug;15(8):1607-1619. doi: 10.1111/jth.13749. Epub 2017 Jul 17.


VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group.

Blood. 2013 Mar 21;121(12):2336-9. doi: 10.1182/blood-2012-09-455089. Epub 2013 Jan 24.


Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.

Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.

Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8. Review.


Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. Review.


Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.

Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F.

J Thromb Haemost. 2015 Oct;13(10):1806-14. doi: 10.1111/jth.13062. Epub 2015 Aug 27.


The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.

Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators.

Thromb Haemost. 2011 Aug;106(2):279-88. doi: 10.1160/TH11-02-0057. Epub 2011 Jul 4.


Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.

Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.

Semin Thromb Hemost. 2006 Sep;32(6):636-45. Review.


Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Doruelo AL, Haberichter SL, Christopherson PA, Boggio LN, Gupta S, Lentz SR, Shapiro AD, Montgomery RR, Flood VH.

J Thromb Haemost. 2017 Aug;15(8):1559-1566. doi: 10.1111/jth.13742. Epub 2017 Jun 23.

Supplemental Content

Support Center